VIR - Vir Biotechnology Inc Stock Price, Fair Value and News

$6.26+0.63 (+11.19%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VIR Price Action

Last 7 days

-2.0%

Last 30 days

11.8%

Last 90 days

21.8%

Trailing 12 Months

-32.0%

VIR RSI Chart

VIR Valuation

Market Cap

870.9M

Price/Earnings (Trailing)

-1.74

Price/Sales (Trailing)

51.66

EV/EBITDA

-1.42

Price/Free Cashflow

-1.89

VIR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VIR Fundamentals

VIR Revenue

Revenue (TTM)

16.9M

Rev. Growth (Yr)

-89.92%

Rev. Growth (Qtr)

-80.23%

VIR Earnings

Earnings (TTM)

-499.7M

Earnings Growth (Yr)

23.66%

Earnings Growth (Qtr)

-47.03%

VIR Profitability

Operating Margin

95.58%

EBT Margin

-2961.95%

Return on Equity

-62.76%

Return on Assets

-49.01%

Free Cashflow Yield

-52.87%

VIR Investor Care

Shares Dilution (1Y)

1.02%

Diluted EPS (TTM)

-3.61

VIR Alerts

2 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	20.9M	19.0M	16.9M	0
2024	79.6M	78.9M	78.6M	74.2M
2023	1.1B	490.7M	118.8M	86.2M
2022	2.3B	2.1B	1.9B	1.6B
2021	331.1M	585.9M	840.7M	1.1B
2020	10.1M	75.1M	75.6M	76.4M
2019	11.9M	11.7M	10.2M	8.1M
2018	4.7M	6.7M	8.7M	10.7M
2017	0	0	0	2.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Vir Biotechnology Inc

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.

CEO	Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
WEBSITE	vir.bio
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	576

Vir Biotechnology Inc Frequently Asked Questions

What is the ticker symbol for Vir Biotechnology Inc? What does VIR stand for in stocks?

VIR is the stock ticker symbol of Vir Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vir Biotechnology Inc (VIR)?

As of Wed Dec 03 2025, market cap of Vir Biotechnology Inc is 870.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIR stock?

You can check VIR's fair value in chart for subscribers.

Is Vir Biotechnology Inc a good stock to buy?

The fair value guage provides a quick view whether VIR is over valued or under valued. Whether Vir Biotechnology Inc is cheap or expensive depends on the assumptions which impact Vir Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIR.

What is Vir Biotechnology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, VIR's PE ratio (Price to Earnings) is -1.74 and Price to Sales (PS) ratio is 51.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIR PE ratio will change depending on the future growth rate expectations of investors.